Neuroprotection Therapeutics

Neuroprotection Therapeutics


Global Neuroprotection Therapeutics Market to Reach US$118.6 Billion by 2030

The global market for Neuroprotection Therapeutics estimated at US$74.5 Billion in the year 2023, is expected to reach US$118.6 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2023-2030. Free Radical Trapping Agents (Antioxidants), one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$45.7 Billion by the end of the analysis period. Growth in the Glutamate Antagonists (Anti-Excitotoxic Agents) segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$20.4 Billion While China is Forecast to Grow at 6.4% CAGR

The Neuroprotection Therapeutics market in the U.S. is estimated at US$20.4 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$18.3 Billion by the year 2030 trailing a CAGR of 6.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.6% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Global Neuroprotection Therapeutics Market - Key Trends & Drivers Summarized

What Are Neuroprotection Therapeutics, and Why Are They So Crucial in Modern Neurology?

Neuroprotection therapeutics are treatments designed to preserve the structure and function of neurons in the central and peripheral nervous systems. These therapies aim to prevent, delay, or reduce neuronal damage caused by neurodegenerative diseases, traumatic injuries, stroke, and other neurological conditions. Neuroprotective agents can include small molecules, biologics, gene therapies, and nutraceuticals that work through various mechanisms, such as reducing oxidative stress, inhibiting excitotoxicity, managing inflammation, or promoting neural repair and regeneration.

The importance of neuroprotection therapeutics lies in their potential to alter the course of neurological diseases, improve quality of life, and reduce healthcare costs by minimizing disability and dependence. In conditions like Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and ischemic stroke, neuroprotection strategies aim to slow down disease progression and maintain cognitive and motor function. As the global prevalence of neurodegenerative and neurological disorders continues to rise due to aging populations and lifestyle factors, the need for effective neuroprotection therapies has become increasingly urgent in modern healthcare.

How Are Technological Advancements Shaping the Neuroprotection Therapeutics Market?

Technological advancements have significantly enhanced the development, delivery, and efficacy of neuroprotection therapeutics, driving innovation in the treatment of neurological diseases. One of the major developments is the rise of precision medicine, which uses genetic profiling, biomarkers, and personalized approaches to tailor neuroprotective treatments to individual patients. Precision medicine has enabled the identification of specific molecular targets and pathways involved in neuronal damage, allowing for more targeted and effective therapies. For instance, gene therapy and RNA-based treatments are being developed to address genetic mutations linked to neurodegenerative diseases like Huntington’s disease and amyotrophic lateral sclerosis (ALS), providing personalized options for disease modification.

The development of biologics, such as monoclonal antibodies and neurotrophic factors, has further expanded the scope of neuroprotection. Biologics offer targeted action against pathogenic proteins and inflammatory processes, reducing neuronal damage in diseases like Alzheimer’s and Parkinson’s. For example, monoclonal antibodies targeting beta-amyloid and tau proteins are under investigation for their potential to slow the progression of Alzheimer’s disease by clearing toxic protein aggregates from the brain. Similarly, neurotrophic factors are being explored for their ability to support neuron survival, promote axonal growth, and enhance synaptic connectivity, offering new avenues for treating conditions like spinal cord injury and multiple sclerosis.

Advancements in drug delivery systems have also improved the effectiveness of neuroprotection therapeutics. Novel delivery methods, such as intranasal administration, liposomal encapsulation, and nanoparticle-based carriers, allow for more efficient transport of therapeutic agents across the blood-brain barrier (BBB). Overcoming the BBB is a significant challenge in neuroprotection, as many potential treatments fail to reach therapeutic concentrations within the central nervous system. Innovations in delivery technologies not only enhance drug bioavailability but also reduce systemic side effects, making neuroprotection therapies safer and more effective. These advancements align with broader trends toward targeted, personalized, and minimally invasive treatment strategies in neurology, supporting better patient outcomes in managing neurodegenerative and acute neurological conditions.

What Are the Emerging Applications of Neuroprotection Therapeutics Across Neurological Disorders?

Neuroprotection therapeutics are finding expanding applications across a range of neurological disorders, driven by the need for more effective treatments that go beyond symptom management to alter disease progression. In the field of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, neuroprotection aims to slow neuronal loss and maintain cognitive and motor functions. Agents targeting oxidative stress, mitochondrial dysfunction, and protein misfolding are being developed to protect neurons and delay disease progression. For example, antioxidants like coenzyme Q10 and glutathione precursors are used to reduce oxidative damage in Parkinson’s patients, while beta-amyloid-clearing agents are being tested in clinical trials for Alzheimer’s.

In the treatment of acute neurological conditions, such as ischemic stroke and traumatic brain injury (TBI), neuroprotection therapeutics aim to limit the extent of neuronal damage and enhance recovery. Stroke treatments, such as neuroprotective peptides and NMDA receptor antagonists, seek to reduce excitotoxicity and limit the infarct size, improving patient outcomes when used alongside reperfusion therapies. Similarly, in TBI management, neuroprotective agents focus on reducing inflammation, controlling intracranial pressure, and supporting neural repair, thereby improving survival rates and reducing long-term disability.

Neuroprotection is also being applied in the management of autoimmune and inflammatory neurological disorders, such as multiple sclerosis (MS). Therapies targeting immune modulation and neural repair are being developed to not only control relapses but also protect against long-term neurodegeneration. For example, neuroprotective agents like anti-inflammatory cytokines and neurotrophic factors are being explored to prevent axonal damage and promote remyelination in MS patients. Additionally, neuroprotection strategies are gaining traction in neurodevelopmental disorders, such as Rett syndrome and fragile X syndrome, where early intervention with neuroprotective agents aims to enhance neurodevelopmental outcomes and improve quality of life.

The expanding applications of neuroprotection therapeutics across these diverse neurological conditions highlight their critical role in supporting long-term disease management, improving patient outcomes, and reducing the societal burden of neurological disorders. By focusing on preserving neuronal function and enhancing recovery, neuroprotection strategies offer hope for patients and caregivers seeking more effective solutions for managing complex neurological diseases.

What Drives Growth in the Neuroprotection Therapeutics Market?

The growth in the neuroprotection therapeutics market is driven by several factors, including increasing prevalence of neurological disorders, rising demand for disease-modifying treatments, and advancements in drug discovery and delivery. One of the primary growth drivers is the global rise in neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and multiple sclerosis, fueled by aging populations and lifestyle-related risk factors. As the number of patients with chronic neurological conditions continues to increase, the demand for therapies that can slow or prevent disease progression has grown significantly, supporting the development of innovative neuroprotective agents.

The growing focus on disease-modifying treatments in neurology has further fueled demand for neuroprotection therapeutics. Unlike symptomatic treatments, neuroprotective agents aim to preserve neuronal integrity and functionality, offering potential long-term benefits for patients. With healthcare providers and patients seeking therapies that provide more meaningful improvements in quality of life, neuroprotection strategies have gained traction across both chronic and acute neurological conditions. This demand is supported by increased investment in neuroscience research, which has led to the identification of new therapeutic targets and biomarkers that guide the development of more effective neuroprotective agents.

Advancements in drug discovery, development, and delivery technologies have also contributed to market growth by making neuroprotection therapies more accessible and effective. The use of artificial intelligence (AI) and machine learning in drug discovery has accelerated the identification of potential neuroprotective compounds, reducing the time and cost associated with bringing new treatments to market. Innovations in drug delivery, such as nanoparticle carriers, liposomal formulations, and intranasal sprays, have improved the ability of neuroprotective agents to cross the blood-brain barrier and reach target neurons, enhancing their efficacy and safety profiles.

Government support, regulatory incentives, and public-private partnerships have also played a significant role in driving the neuroprotection therapeutics market. Programs aimed at accelerating the development of treatments for neurodegenerative diseases and rare neurological disorders have led to increased funding, expedited clinical trials, and more collaborative research efforts. Regulatory agencies have provided pathways for accelerated approval and orphan drug designation for promising neuroprotective therapies, further encouraging innovation and investment in this field.

With ongoing advancements in neuroscience, personalized medicine, and drug delivery technologies, the neuroprotection therapeutics market is poised for robust growth. These trends, combined with increasing demand for effective treatments that address the underlying causes of neurological disorders, make neuroprotection therapeutics a vital component of modern neurology and long-term disease management strategies across diverse patient populations.

SCOPE OF STUDY:

The report analyzes the Neuroprotection Therapeutics market in terms of US$ Million by the following Application; Product, and Geographic Regions/Countries:

Segments:
Application (Prevention, Treatment); Product (Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs), Other Products)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -
  • Allergan PLC
  • AstraZeneca PLC
  • Astrocyte Pharmaceuticals Inc.
  • Biogen, Inc.
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Novartis International AG
  • Teva Pharmaceutical Industries Ltd.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Neuroprotection Therapeutics – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Neurodegenerative Diseases Drives Demand for Neuroprotection
Increasing Focus on Alzheimers Treatment Sets the Stage for Neuroprotection Growth
Advancements in Stroke Management Propel Neuroprotection Market
Use in Traumatic Brain Injury Treatment Expands Addressable Market
Increasing Applications in Parkinsons Disease Drive Neuroprotection Market
Growing Role of Stem Cell Research Generates Opportunities for Neuroprotection
Use in Neuroinflammatory Disorders Sets the Stage for Market Expansion
Advancements in Neuroimaging Propel Development of Neuroprotective Agents
Expanding Role of Gene Therapy in Neuroprotection Sets the Stage for Growth
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Neuroprotection Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Neuroprotection Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Neuroprotection Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Free Radical Trapping Agents (Antioxidants) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Free Radical Trapping Agents (Antioxidants) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Free Radical Trapping Agents (Antioxidants) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Glutamate Antagonists (Anti-Excitotoxic Agents) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Glutamate Antagonists (Anti-Excitotoxic Agents) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Glutamate Antagonists (Anti-Excitotoxic Agents) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Apoptosis Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Apoptosis Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Apoptosis Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Anti-inflammatory Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Anti-inflammatory Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Anti-inflammatory Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Neurotrophic Factors (NTFs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Neurotrophic Factors (NTFs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Neurotrophic Factors (NTFs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Prevention by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Prevention by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Prevention by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Neuroprotection Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: USA 16-Year Perspective for Neuroprotection Therapeutics by Product - Percentage Breakdown of Value Sales for Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products for the Years 2014, 2024 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Application - Prevention and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: USA Historic Review for Neuroprotection Therapeutics by Application - Prevention and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: USA 16-Year Perspective for Neuroprotection Therapeutics by Application - Percentage Breakdown of Value Sales for Prevention and Treatment for the Years 2014, 2024 & 2030
CANADA
TABLE 35: Canada Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Canada 16-Year Perspective for Neuroprotection Therapeutics by Product - Percentage Breakdown of Value Sales for Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products for the Years 2014, 2024 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Application - Prevention and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Neuroprotection Therapeutics by Application - Prevention and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Canada 16-Year Perspective for Neuroprotection Therapeutics by Application - Percentage Breakdown of Value Sales for Prevention and Treatment for the Years 2014, 2024 & 2030
JAPAN
Neuroprotection Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 41: Japan Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Japan 16-Year Perspective for Neuroprotection Therapeutics by Product - Percentage Breakdown of Value Sales for Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products for the Years 2014, 2024 & 2030
TABLE 44: Japan Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Application - Prevention and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Neuroprotection Therapeutics by Application - Prevention and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Japan 16-Year Perspective for Neuroprotection Therapeutics by Application - Percentage Breakdown of Value Sales for Prevention and Treatment for the Years 2014, 2024 & 2030
CHINA
Neuroprotection Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 47: China Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: China Historic Review for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: China 16-Year Perspective for Neuroprotection Therapeutics by Product - Percentage Breakdown of Value Sales for Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products for the Years 2014, 2024 & 2030
TABLE 50: China Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Application - Prevention and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: China Historic Review for Neuroprotection Therapeutics by Application - Prevention and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: China 16-Year Perspective for Neuroprotection Therapeutics by Application - Percentage Breakdown of Value Sales for Prevention and Treatment for the Years 2014, 2024 & 2030
EUROPE
Neuroprotection Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 53: Europe Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Neuroprotection Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for Neuroprotection Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Europe 16-Year Perspective for Neuroprotection Therapeutics by Product - Percentage Breakdown of Value Sales for Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products for the Years 2014, 2024 & 2030
TABLE 59: Europe Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Application - Prevention and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Neuroprotection Therapeutics by Application - Prevention and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Europe 16-Year Perspective for Neuroprotection Therapeutics by Application - Percentage Breakdown of Value Sales for Prevention and Treatment for the Years 2014, 2024 & 2030
FRANCE
Neuroprotection Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 62: France Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: France Historic Review for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: France 16-Year Perspective for Neuroprotection Therapeutics by Product - Percentage Breakdown of Value Sales for Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products for the Years 2014, 2024 & 2030
TABLE 65: France Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Application - Prevention and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: France Historic Review for Neuroprotection Therapeutics by Application - Prevention and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: France 16-Year Perspective for Neuroprotection Therapeutics by Application - Percentage Breakdown of Value Sales for Prevention and Treatment for the Years 2014, 2024 & 2030
GERMANY
Neuroprotection Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 68: Germany Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Germany 16-Year Perspective for Neuroprotection Therapeutics by Product - Percentage Breakdown of Value Sales for Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products for the Years 2014, 2024 & 2030
TABLE 71: Germany Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Application - Prevention and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Germany Historic Review for Neuroprotection Therapeutics by Application - Prevention and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Germany 16-Year Perspective for Neuroprotection Therapeutics by Application - Percentage Breakdown of Value Sales for Prevention and Treatment for the Years 2014, 2024 & 2030
ITALY
TABLE 74: Italy Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Italy 16-Year Perspective for Neuroprotection Therapeutics by Product - Percentage Breakdown of Value Sales for Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products for the Years 2014, 2024 & 2030
TABLE 77: Italy Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Application - Prevention and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Italy Historic Review for Neuroprotection Therapeutics by Application - Prevention and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Italy 16-Year Perspective for Neuroprotection Therapeutics by Application - Percentage Breakdown of Value Sales for Prevention and Treatment for the Years 2014, 2024 & 2030
UNITED KINGDOM
Neuroprotection Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 80: UK Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: UK Historic Review for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: UK 16-Year Perspective for Neuroprotection Therapeutics by Product - Percentage Breakdown of Value Sales for Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products for the Years 2014, 2024 & 2030
TABLE 83: UK Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Application - Prevention and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: UK Historic Review for Neuroprotection Therapeutics by Application - Prevention and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: UK 16-Year Perspective for Neuroprotection Therapeutics by Application - Percentage Breakdown of Value Sales for Prevention and Treatment for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Rest of Europe Historic Review for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Rest of Europe 16-Year Perspective for Neuroprotection Therapeutics by Product - Percentage Breakdown of Value Sales for Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products for the Years 2014, 2024 & 2030
TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Application - Prevention and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Rest of Europe Historic Review for Neuroprotection Therapeutics by Application - Prevention and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Rest of Europe 16-Year Perspective for Neuroprotection Therapeutics by Application - Percentage Breakdown of Value Sales for Prevention and Treatment for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Neuroprotection Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Asia-Pacific Historic Review for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Asia-Pacific 16-Year Perspective for Neuroprotection Therapeutics by Product - Percentage Breakdown of Value Sales for Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products for the Years 2014, 2024 & 2030
TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Application - Prevention and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Asia-Pacific Historic Review for Neuroprotection Therapeutics by Application - Prevention and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Asia-Pacific 16-Year Perspective for Neuroprotection Therapeutics by Application - Percentage Breakdown of Value Sales for Prevention and Treatment for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 98: Rest of World Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Rest of World Historic Review for Neuroprotection Therapeutics by Product - Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Rest of World 16-Year Perspective for Neuroprotection Therapeutics by Product - Percentage Breakdown of Value Sales for Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs) and Other Products for the Years 2014, 2024 & 2030
TABLE 101: Rest of World Recent Past, Current & Future Analysis for Neuroprotection Therapeutics by Application - Prevention and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Rest of World Historic Review for Neuroprotection Therapeutics by Application - Prevention and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Rest of World 16-Year Perspective for Neuroprotection Therapeutics by Application - Percentage Breakdown of Value Sales for Prevention and Treatment for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings